Breaking News

Cambrex Facility Completes FDA Inspection

IA site GMP compliant, with no Form 483 observations

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cambrex Corp. has successfully completed an FDA inspection of its API manufacturing facility in Charles City, IA. The inspection found the site to be compliant with GMP principles and guidelines, with no Form 483 observations issued. The FDA inspected the facility from July 31 to August 2, 2013.   Joe Nettleton, Cambrex’ vice president operations and Charles City site director, said, “We are very pleased with the results of this latest FDA inspection, which further strengthens our track re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters